Hepcidin Levels in Preterm Infants

Hepcidin Levels in Preterm Infants Receiving Blood Transfusion and During Sepsis.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01539356

Enrollment

Registered

2012-02-27

Start date

2012-03-31

Completion date

2013-08-31

Last updated

2016-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia of Prematurity, Neonatal Sepsis, Preterm Infants

Keywords

Hepcidin, Preterm Infants, Anemia, Sepsis, Ferritin

Brief summary

A recently isolated peptide hormone, hepcidin, is thought to be the principal regulator of iron homeostasis. Hepcidin acts by limiting intestinal iron absorption and promoting iron retention in reticuloendothelial cells. The aims of this study were to determine serum hepcidin levels in preterm infants who receive blood transfusion and preterm infants having sepsis, in order to assess possible relationships between hepcidin and serum iron, serum ferritin,in iron load situations.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

24 Weeks to 37 Weeks

Healthy volunteers

Inclusion criteria

* Preterm \< 38 weeks gestation * Need of blood test for anemia or suspected sepsis

Exclusion criteria

* Major congenital anomalies * Birth Asphyxia

Design outcomes

Primary

Measure	Time frame
Increase in Hepcidin levels by 30%	within 24-72 h

Countries

Israel

Outcome results